[go: up one dir, main page]

WO2010057922A1 - Composition durcissable comprenant une base thermolatente - Google Patents

Composition durcissable comprenant une base thermolatente Download PDF

Info

Publication number
WO2010057922A1
WO2010057922A1 PCT/EP2009/065394 EP2009065394W WO2010057922A1 WO 2010057922 A1 WO2010057922 A1 WO 2010057922A1 EP 2009065394 W EP2009065394 W EP 2009065394W WO 2010057922 A1 WO2010057922 A1 WO 2010057922A1
Authority
WO
WIPO (PCT)
Prior art keywords
substituted
alkyl
aryl
interrupted
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2009/065394
Other languages
English (en)
Other versions
WO2010057922A4 (fr
Inventor
Peter Nesvadba
Lucienne Bugnon Folger
Ralf Knischka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF SE
Original Assignee
BASF SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BASF SE filed Critical BASF SE
Priority to EP09755900A priority Critical patent/EP2367794B1/fr
Priority to KR1020117014449A priority patent/KR101239571B1/ko
Priority to CN200980147096.1A priority patent/CN102224140B/zh
Priority to ES09755900T priority patent/ES2400633T3/es
Priority to BRPI0921185A priority patent/BRPI0921185A2/pt
Priority to US13/130,331 priority patent/US8969577B2/en
Priority to PL09755900T priority patent/PL2367794T3/pl
Priority to JP2011536854A priority patent/JP5250116B2/ja
Publication of WO2010057922A1 publication Critical patent/WO2010057922A1/fr
Publication of WO2010057922A4 publication Critical patent/WO2010057922A4/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G59/00—Polycondensates containing more than one epoxy group per molecule; Macromolecules obtained by polymerising compounds containing more than one epoxy group per molecule using curing agents or catalysts which react with the epoxy groups
    • C08G59/18—Macromolecules obtained by polymerising compounds containing more than one epoxy group per molecule using curing agents or catalysts which react with the epoxy groups ; e.g. general methods of curing
    • C08G59/68—Macromolecules obtained by polymerising compounds containing more than one epoxy group per molecule using curing agents or catalysts which react with the epoxy groups ; e.g. general methods of curing characterised by the catalysts used
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G59/00—Polycondensates containing more than one epoxy group per molecule; Macromolecules obtained by polymerising compounds containing more than one epoxy group per molecule using curing agents or catalysts which react with the epoxy groups
    • C08G59/18—Macromolecules obtained by polymerising compounds containing more than one epoxy group per molecule using curing agents or catalysts which react with the epoxy groups ; e.g. general methods of curing
    • C08G59/40—Macromolecules obtained by polymerising compounds containing more than one epoxy group per molecule using curing agents or catalysts which react with the epoxy groups ; e.g. general methods of curing characterised by the curing agents used
    • C08G59/42—Polycarboxylic acids; Anhydrides, halides or low molecular weight esters thereof
    • C08G59/4246—Polycarboxylic acids; Anhydrides, halides or low molecular weight esters thereof polymers with carboxylic terminal groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G59/00—Polycondensates containing more than one epoxy group per molecule; Macromolecules obtained by polymerising compounds containing more than one epoxy group per molecule using curing agents or catalysts which react with the epoxy groups
    • C08G59/18—Macromolecules obtained by polymerising compounds containing more than one epoxy group per molecule using curing agents or catalysts which react with the epoxy groups ; e.g. general methods of curing
    • C08G59/68—Macromolecules obtained by polymerising compounds containing more than one epoxy group per molecule using curing agents or catalysts which react with the epoxy groups ; e.g. general methods of curing characterised by the catalysts used
    • C08G59/686—Macromolecules obtained by polymerising compounds containing more than one epoxy group per molecule using curing agents or catalysts which react with the epoxy groups ; e.g. general methods of curing characterised by the catalysts used containing nitrogen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K5/00—Use of organic ingredients
    • C08K5/16—Nitrogen-containing compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L63/00—Compositions of epoxy resins; Compositions of derivatives of epoxy resins
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
    • C09D163/00—Coating compositions based on epoxy resins; Coating compositions based on derivatives of epoxy resins

Definitions

  • Curable Composition comprising a thermolatent base
  • the present invention relates to curable compositions comprising a thermolatent amidine base and an organic material which is polymerisable or crosslinkable with a basic or nucleophilic catalyst.
  • the invention relates to curable coating compositions, especially powder coating compositions, and curable adhesive compositions, as well as to the use a thermolatent amidine base as a curing catalyst for thermally induced base- catalysed polymerisation or crosslinking reactions.
  • thermolatent bases Compounds from which bases are released by heating are referred to as thermolatent bases.
  • Thermolatent bases are employed in various systems designed so that the bases released by heating can function therein. Examples of such systems include heat-developable photographic materials, heat sensitive recording materials, anion-polymerisable adhesives, film formation by coating, sealing materials, caulking materials, and the like.
  • thermolatent bases for use in various types of image-forming materials for which heat is utilized are salts of carboxylic acids and organic bases, as described, for example, in GB 998,949 (trichloroacetic acid salts), US-B-6,699,651 ( ⁇ -sulfonylacetic acid salts).
  • DE-A-35 30 252 describes salts comprising as a thermolatent base a protonated guanidine, an amidine or a cyclic derivative thereof. The use of these salts stems from the fact that decarboxylation of the carboxylic acids by heating results in the release of the organic bases.
  • Other thermolatent bases include 2-carboxycarboxamide derivatives disclosed in US-A-4,088,496, hydroxamic acid carbamates disclosed in EP-A-O 120 661 and aldoxime carbamates disclosed in EP-A-O 118 078.
  • WO 98/04531 discloses curable mixtures based on epoxy resins comprising a N-alkoxy- carbonyl imidazole as a curing catalyst which release an imidazole derivative by decarboxylation.
  • US-A-4, 189,543 also describes the use of such compounds in making polyurethane foams.
  • thermolatent base as a curing catalyst
  • thermolatent bases exhibiting good stability during storage in curable compositions but in addition rapid conversion into the active bases when heated at the temperature of use.
  • the present invention is directed to a curable composition
  • a curable composition comprising (A) an organic material which is polymerisable or crosslinkable with a basic or nucleophilic catalyst and (B) a compound of the formula
  • R 1 forms together with the carbon and nitrogen atom, it is linked to, a mono- or polycyclic C 2 -C 2 oring system, which may further contain one or more heteroatoms of O, S and/or N and/or may be unsubstituted or substituted by
  • C 2 -Ci 8 heteroaryl which is substituted by G
  • R 2 , R 3 , R 4 and R 5 are independently of each other and in each occurrence H; Ci-Ci ⁇ alkyl; Ci-Ci 8 alkyl, which is substituted by E and/or interrupted by D; C 5 -Ci 2 cycloalkyl; C 5 -Ci 2 cycloalkyl, which is substituted by E; C 6 -Ci 2 aryl; C 6 -Ci8aryl, which is substituted by G; C 2 -Ci 8 heteroaryl; C 2 -Ci 8 heteroaryl, which is substituted by G; Ci-Ci 8 alkoxy; Ci-Ci 8 alkoxy, which is substituted by E and/or interrupted by D; C 7 -Ci 8 aralkyl; C 7 -Ci 8 aralkyl, which is substituted by G; NHR 18 , NR 19 R 20 , COOH;
  • R 2 and R 3 , R 4 and R 5 , or R 2 and R 4 form an organic bridging group completing, together with the carbon atom, they are linked to, a carbocyclic or heterocyclic ring of 5 to 12 ring atoms in total; or two of R 5 , which are linked to adjacent carbon atoms, form an organic bridging group completing, together with the carbon atom, they are linked to, a carbocyclic or heterocyclic ring of 5 to 12 ring atoms in total;
  • E is OR 27 ; SR 28 ; SOR 29 ; SO 2 R 30 ; NR 31 R 32 ; COR 33 ; COOR 34 ; CONR 35 R 36 ; PO(R 37 ) 2 ; Si(R 38 ) 3 ;
  • G is E or Ci-Ci 8 alkyl
  • R 27 , R 28 , R 29 , R 30 , R 31 , R 32 , R 33 , R 34 , R 35 R 36 , R 37 and R 38 are independently of each other Ci-Ci 8 alkyl; Ci-Ci 8 alkyl, which is interrupted by -0-; C 6 -Ci 8 aryl; C 6 -Ci 8 aryl, which is substituted by Ci-Ci 8 alkyl or Ci-Ci 8 alkoxy; C 7 -Ci 8 aralkyl; C 7 -Ci 8 aralkyl, which is substituted by G; C 2 -C 18 heteroaryl;
  • R 7 and R 8 , R 9 and R 10 , R 16 and R 17 , R 19 and R 20 , R 31 and R 32 , or R 35 and R 36 form an organic bridging group completing, together with the nitrogen atom, they are linked to, a heterocyclic ring of 5 to 7 ring atoms in total;
  • L is a n-valent leaving group, n is an integer of 1 , 2, 3 or 4; and p is an integer of 1 , 2, 3 or 4.
  • the compounds of formula (I) are essentially inactive at room temperature or at slightly elevated temperature and do not promote polymerisation until the composition according to the invention is heated. At elevated temperatures they release a compound of the formula (V) according to the following reaction scheme:
  • the compounds of formula (V) contain the structure of a cyclic amidine and are therefore sufficiently basic or nucleophilic to initiate a large number of base-catalysed polymerisation or crosslinking reactions.
  • the temperature range where these bases are released and where they are active may be varied within a wide range by the choice of the substitution pattern.
  • compounds of formula (I) enable to prepare so-called one-pot systems with base- polymerisable oligomers or monomers having an extremely long storage life without special precautions.
  • such systems offer an advantage in terms of reduced handling prior immediate use and lower amounts of waste due to better pot-life.
  • the systems may be formulated with little or no solvent, since the compounds can be dissolved in the monomers or oligomers without being affected.
  • These systems may be employed for numerous purposes, especially for coatings, more especially for powder coatings.
  • reaction temperatures required to activate the catalyst may be of from about 50 0 C to about 250 0 C.
  • the preferred temperature range is of from about 80 0 C to about 150 0 C, more preferable of from about 110 0 C to about 130 0 C.
  • thermolatent base also designated as “thermal base precursor” refers to a neutral or weakly basic or weakly nucleophilic compound which releases a basic or nucleophilic compound upon heating.
  • the invention is directed to a curable composition
  • a curable composition comprising as a component (B) a compound of formula (I), wherein, if n is 1 , L is halogen, OH, OR 40 , SR 40 , OCOR 40 , OCOOR 41 , OCONR 42 R 43 , OCSNR 42 R 43 ,
  • R 40 , R 42 , R 43 , R 44 , R 45 , R 46 and R 47 are independently of each other H, C r Ci 8 alkyl or
  • Ci-Ci 8 alkyl which is substituted by E and/or interrupted by D; C 5 -Ci 2 cycloalkyl,
  • C 5 -Ci 2 cycloalkyl which is substituted by E and/or interrupted by D
  • C 6 -Ci 8 aryl C 6 -Ci 8 aryl, which is substituted by G
  • C 7 -Ci 8 aralkyl C 7 -Ci 8 aralkyl, which is substituted by G;
  • R 42 and R 43 form an organic bridging group completing, together with the nitrogen atom, they are linked to, a heterocyclic ring of 5 to 7 ring atoms in total; or two of R 45 form a bridging group completing, together with the -OC-N-CO- group, they are linked to, a heterocyclic ring of 5 to 7 ring atoms in total;
  • R 41 is Ci-Ci 8 alkyl or Ci-Ci 8 alkyl, which is substituted by E and/or interrupted by D;
  • X " is halide, hydroxide, C r Ci 8 alkylsulfonate, C 6 -Ci 8 arylsulfonate, R 4 XOO " , HSO 4 " or Vi SO 4 2- , wherein R 48 is H, Ci-Ci 8 alkyl or Ci-Ci 8 alkyl, which is substituted by E and/or interrupted by D; C 5 -Ci 2 cycloalkyl, C 5 -Ci 2 cycloalkyl, which is substituted by E and/or interrupted by D; C 6 -Ci 8 aryl; C 6 -Ci 8 aryl, which is substituted by G; C 2 -Ci 8 heteroaryl; C 2 -Ci 8 heteroaryl, which is substituted by G; OO-
  • R 1 Il is a mono- or polycyclic C 2 -C 20 ring system, which,
  • the N may contain one or more heteroatoms of O, S and/or N and/or may be unsubstituted or substituted, as specified in claim 1.
  • the ring system may be an aromatic or non-aromatic heterocyclic system.
  • the C 2 -C 2 oring system comprises 1 to 4 annellated rings and up to 5 heteroatoms selected from O, N and/or S. More preferred, the C 2 -C 2 oring system comprises 1 to 3, for example 1 or 2, annellated rings and 1 to 3, for example 1 or 2, heteroatoms selected from N and/or S.
  • Alkyl groups may be within the given limits of carbon atoms linear or branched, where possible. Examples are methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, 2,2-dimethylpropyl, 1 ,1 ,3,3-tetramethylpentyl, n-hexyl, 1-methylhexyl, 1 ,1 ,3,3,5,5-hexamethylhexyl, n-heptyl, isoheptyl, 1 ,1 ,3,3-tetramethylbutyl, 1-methylheptyl, 3-methylheptyl, n-octyl, 1 ,1 ,3,3-tetramethylbutyl and 2-ethylhexyl, n-nonyl, decyl, undec
  • Cycloalkyl groups may be within the given limits, for example, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, methylcyclopentyl, dimethylcyclopentyl, methylcyclohexyl and dimethylcyclohexyl, preferably cyclohexyl.
  • the cycloalkyl group in particular a cyclohexyl group, may be condensed one or twice by phenyl which may be substituted one to three times with d-C 4 alkyl and halogen.
  • Cycloalkenyl groups may be within the given limits, for example, cyclopentenyl, cyclohexenyl, methylcyclopentenyl, dimethylcyclopentenyl and methylcyclohexenyl. Cycloalkenyl may comprise more than one double bond that may be conjugated or non-conjugated, for example may comprise one double bond. Alkenyl groups may be within the given limits of carbon atoms straight-chain or branched, where possible.
  • alkenyl also comprises residues with more than one double bond that may be conjugated or non-conjugated, for example may comprise one double bond.
  • Alkynyl groups may be within the given limits of carbon atoms straight-chain or branched, where possible. Examples are ethynyl, 1-propyn-3-yl, 1-butyn-4-yl, 1-pentyn-5-yl, 2-methyl-3- butyn-2-yl, 1 ,4-pentadiyn-3-yl, 1 ,3-pentadiyn-5-yl, 1-hexyn-6-yl, cis-3-methyl-2-penten-4-yn- 1-yl, trans-3-methyl-2-penten-4-yn-1-yl, 1 ,3-hexadiyn-5-yl, 1-octyn-8-yl, 1-nonyn-9-yl or 1- decyn-10-yl.
  • alkynyl also comprises residues with more than one triple bond and residues with a triple bond and a double bond, all of which may be conjugated or non- conjugated. For instance, al
  • aryl group is typically C 6 -Ci 8 aryl, such as phenyl, indenyl, azulenyl, naphthyl, biphenyl or terphenylyl, as-indacenyl, s-indacenyl, acenaphthylenyl, phenanthryl, fluoranthenyl, triphenylenyl, chrysenyl, naphthacen, picenyl, perylenyl, pentaphenyl, hexacenyl, pyrenyl, or anthracenyl, preferably phenyl, 1 -naphthyl, 2-naphthyl, 9-phenanthryl, 2- or 9-fluorenyl, 3- or 4-biphenyl.
  • Alkoxy groups may be within the given limits of carbon atoms straight-chain or branched alkoxy groups, e.g. methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, isobutoxy, tert-butoxy, amyloxy, isoamyloxy or tert-amyloxy, heptyloxy, octyloxy, isooctyloxy, nonyloxy, decyloxy, undecyloxy, dodecyloxy, tetradecyloxy, pentadecyloxy, hexadecyloxy, heptadecyloxy and octadecyloxy.
  • alkylthio group means the same groups as the alkoxy groups, except that the oxygen atom of the ether linkage is replaced by a sulfur atom.
  • Aralkyl groups may be within the given limits of carbon atoms, for example, benzyl, 2-benzyl-2-propyl, ⁇ -phenyl-ethyl (phenethyl), ⁇ , ⁇ -dimethylbenzyl, ⁇ -phenyl-butyl, ⁇ , ⁇ -dimethyl- ⁇ -phenyl-butyl, ⁇ -phenyl-dodecyl, in which both the aliphatic and the aromatic hydrocarbon group may be unsubstituted or substituted.
  • Preferred examples are benzyl, phenethyl and ⁇ , ⁇ -dimethylbenzyl.
  • heteroaryl group is a ring, wherein nitrogen, oxygen or sulfur are the possible hetero atoms, and is typically an unsaturated heterocyclic radical with five to 18 atoms having at least six conjugated ⁇ -electrons such as thienyl, benzo[b]thienyl, dibenzo[b,d]thienyl, thianthrenyl, furyl, furfuryl, 2H-pyranyl, benzofuranyl, isobenzofuranyl, 2H-chromenyl, xanthenyl, dibenzofuranyl, phenoxythienyl, pyrrolyl, imidazolyl, pyrazolyl, pyridyl, bipyridyl, triazinyl, pyrimidinyl, pyrazinyl, 1 H-pyrrolizinyl, isoindolyl, pyridazinyl, indolizinyl
  • Halogen denotes I, Br, Cl, F, especially, Br or Cl.
  • Examples of a 5 to 12 membered ring formed by R 2 and R 3 , R 4 and R 5 , R 2 and R 4 or two of R 5 are cycloalkanes which may have one additional hetero atom selected from NR', O and S, wherein R' is Ci-Ci 8 alkyl or phenyl, and/or said ring may be substituted by E and/or interrupted by D.
  • Preferred are 5 to 7 membered cycloalkanes.
  • Examples of a 5 to 7 membered ring formed by R 7 and R 8 , R 9 and R 10 , R 16 and R 17 , R 19 and R 20 , R 31 and R 32 , R 35 and R 36 , or R 42 and R 43 are heterocycloalkanes or heterocycloalkenes having 3 to 6 carbon atoms and optionally one additional hetero atom selected from NR', O and S, wherein R' is Ci-Ci 8 alkyl or phenyl; said 5 to 7 membered ring may be substituted by E and/or interrupted by D. Examples are , or N ' I , which may be part of a bicyclic
  • Examples of a 5 to 7 membered ring formed by two of R ->45 are heterocycloalkanes or
  • N ' L 1 O heterocycloalkenes having from 3 to 6 carbon atoms, for example, N ' L 1 , which may be
  • R 4 and R 5 means that the radicals R 4 and R 5 may have independently from each other different meanings, if p is 2, 3 or 4.
  • radicals may be substituted by E and/or, if desired, interrupted by D.
  • Interruptions are of course possible only in the case of radicals containing at least 2 carbon atoms connected to one another by single bonds; C ⁇ -Cisaryl is not interrupted; interrupted arylalkyl or alkylaryl contains the unit D in the alkyl moiety, d- C-isalkyl substituted by one or more E and/or interrupted by one or more units D is, for example, (CH 2 CH 2 O ) S -R X , wherein s is a number from the range 1-9 and R x is H or d- Cioalkyl or C 2 -d 0 alkanoyl (e.g.
  • R y is C r Ci 8 alkyl, C 5 -Ci 2 cycloalkyl, phenyl, C 7 -Ci 5 phenylalkyl, and R y ' embraces the same definitions as R y or is H; C r C 8 alkylene-COO-R z , e.g.
  • the term "at least" is intended to define one or more than, e.g. one or two or three, preferably one or two.
  • the curable composition comprises as a component (B) a compound of formula (I), wherein R 2 , R 3 , R 4 and R 5 are independently of each other H; d- C 8 alkyl; C 5 -C 8 cycloalkyl; C 6 -Ci 8 aryl; C 6 -Ci 8 aryl, which is substituted by G; C 2 -Ci 8 heteroaryl; C 2 -Ci 8 heteroaryl, which is substituted by G; C r C 4 alkoxy; C 7 -Ci 0 aralkyl; NHR 6 , NR 7 R 8 , wherein R 6 , R 7 and R 8 are independently of each other d-C 4 alkyl; C 6 -Ci 2 aryl; C 6 -Ci 2 aryl, which is substituted by Ci-C 4 alkyl or Ci-C 4 alkoxy; C 7 -Ci 0 aralkyl; or R 7 and R 8 form an organic bridging
  • R 2 and R 3 , R 4 and R 5 , or R 2 and R 4 form an organic bridging group completing, together with the carbon atom, they are linked to, a carbocyclic or heterocyclic ring of 5 to 7 ring atoms in total; or two of R 5 , which are linked to adjacent carbon atoms, form an organic bridging group completing, together with the carbon atom, they are linked to, a carbocyclic or heterocyclic ring of 5 to 7 ring atoms in total;
  • the composition comprises as a component (B) a compound of formula (I), wherein R 2 , R 3 , R 4 and R 5 are independently of each other H or Ci-C 4 alkyl, and p is an integer of 1 or 2.
  • compositions comprising as a component (B) a compound of formula (I), wherein R 1 is a mono- or polycyclic C 2 -C 2 oring system selected from the group consisting of imidazole, benzimidazole, thiazole, benzothiazole, pyrazole, oxazole, benzoxazole, isoxazole, isothiazole, 1 ,2,3-triazole, 1 ,2,4- triazole, tetrazole, 1 ,2,4-oxadiazole, 1 ,2,4-thiadiazole, 1 ,3,4-oxadiazole, 1 ,3,4-thiadiazole, pyridine, quinoline, isoquinoline, phenanthridine, pyridazine, pyrimidine, pyrazine, cinnoline, phthalazine, chinazoline, chinoxaline, chinazolinone, 1 ,3,5-
  • R 1 is a mono
  • said ring system is unsubstituted or substituted by Ci-C 8 alkyl; C 5 -C 7 cycloalkyl; C 6 -Ci 2 aryl; C 6 - Ci 8 aryl, which is substituted by G; C 2 -Ci 8 heteroaryl; C 2 -Ci 8 heteroaryl, which is substituted by G; Ci-C 8 alkoxy; Ci-C 8 alkoxy, which is substituted by E and/or interrupted by D; C 7 -Cnaralkyl; C 7 -Ciiaralkyl, which is substituted by G; halogen, OH, oxo, CN, NH 2 , NHR 6 , NR 7 R 8 , CONH 2 , CONR 9 R 10 , COR 11 , C(O)OR 12 , wherein R 6 , R 7 , R 8 , R 9 , R 10 , R 11 and R 12 are independently of each other C r C 8 alkyl; C r
  • C 8 alkyl which is interrupted by -0-; C 6 -Ci 2 aryl; C 6 -Ci 2 aryl, which is substituted by Ci-C 8 alkyl or Ci-C 8 alkoxy; C 7 -Cnaralkyl; C 7 -Cnaralkyl, which is substituted by G; or R 7 and R 8 form an organic bridging group completing, together with the nitrogen atom, they are linked to, a heterocyclic ring of 5 to 7 ring atoms in total; or said ring system is further anellated by one or more benzene rings.
  • compositions comprising as a component (B) a compound of formula (I), wherein R 1 is a mono- or polycyclic Ci-C 20 ring system selected from the group consisting of imidazole, benzimidazole, thiazole, benzothiazole, oxazole, benzoxazole, isothiazole, pyridine, chinoline, isochinoline, phenanthridine, pyridazine, pyrimidine, pyrazine, cinnoline, phthalazine, chinazoline, chinoxaline, purine, 1 ,10-phenanthroline, 2,2'-bipyridine and 4,4'- bipyridine; said ring system is unsubstituted or substituted by Ci-C 4 alkyl; phenyl; phenyl, which is substituted by Ci-C 4 alkyl, Ci-C 4 alkoxy or halogen; Ci-C 4 alkoxy; benzyl;
  • compositions comprising as a component (B) a compound of formula (I), wherein n is 1 and L is halogen, OH, OR 40 , SR 40 , OCOR 40 , OCOOR 41 , OCONR 42 R 43 , OCSNR 42 R 43 , NR 42 R 43 , wherein R 40 , R 42 , R 43 are independently of each other H, d-C 8 alkyl; phenyl; or benzyl.
  • a component (B) a compound of formula (I), wherein n is 1 and L is halogen, OH, OR 40 , SR 40 , OCOR 40 , OCOOR 41 , OCONR 42 R 43 , OCSNR 42 R 43 , NR 42 R 43 , wherein R 40 , R 42 , R 43 are independently of each other H, d-C 8 alkyl; phenyl; or benzyl.
  • compositions comprising as a component (B) a compound of formula (I), wherein n is 1 and L is halogen, OH, OMe, SMe, NH 2 , NMe 2 , OCOMe, OCOPh, OCOtBu, OCSNMe 2 , OCONMe 2 , OCONHMe, OCONHEt, OCONHPh, OCOOMe, OCOOtBu, OCOOPh, OCOOCH 2 Ph.
  • thermolatent bases examples include (1-1 ). (I-2),
  • L is as defined above, preferably halogen, OH, OMe, SMe, NH 2 , NMe 2 , OCOMe, OCOPh, OCOtBu, OCSNMe 2 , OCONMe 2 , OCONHMe, OCONHEt, OCONHPh, OCOOMe, OCOOtBu, OCOOPh, OCOOCH 2 Ph.
  • thermolatent bases wherein the mono- or polycyclic C 2 -C 2 oring system is
  • R 5 , L and p are defined, as above, include (11-1 ) and
  • Component (A) i.e. the organic material which is polymerisable or crosslinkable with basic or nucleophilic catalyst, may generally be in the form of mono- or polyfunctional monomers, oligomers or polymers. Particularly preferred oligomeric/polymeric systems are binders or coating systems as are customary in the coatings industry.
  • component (A) is one of the following systems: a) acrylate copolymers having alkoxysilane or alkoxysiloxane side groups, for example the polymers described in US-A-4,772,672 or US-A-4,444,974; b) two-component systems comprising hydroxyl group-containing polyacrylates, polyesters and/or polyethers and aliphatic or aromatic polyisocyanates; c) two-component systems comprising functional polyacrylates and/or polyesters and a polyepoxide, where the polyacrylate and/or the polyester contain(s) carboxyl or anhydride groups; d) two-component systems comprising fluorine-modified or silicone-modified hydroxyl group-containing polyacrylates, polyesters and/or polyethers and aliphatic or aromatic polyisocyanates; e) two-component systems comprising (poly)ketimines and aliphatic or
  • dodecanediacid I) polymers based on allyl glycidyl ether; m) two-component systems comprising a (poly)alcohol and a (poly)isocyanate; n) two-component systems comprising an ⁇ , ⁇ -ethylenically unsaturated carbonyl compound and a polymer which contains activated CH 2 groups, it being possible for the activated CH 2 groups to be present either in the main chain or in the side chain or in both, as is described, for example, in EP-B-O 161 697 for (poly)malonate groups.
  • Other compounds having activated CH 2 groups are (poly)acetoacetates and (poly)cyanoacetates.
  • base-catalysable binders particular preference is given to the following: b) two-component systems comprising hydroxyl group-containing polyacrylates, polyesters and/or polyethers and aliphatic or aromatic polyisocyanates; c) two-component systems comprising functional polyacrylates and/or polyesters and a polyepoxide, where the polyacrylate and/or the polyester contain(s) carboxyl or anhydride groups; i) two-component systems comprising epoxy-containing polyacrylates and carboxyl-group containing polyacrylates or a dicarboxylic acid, e.g.
  • dodecanediacid m) two-component systems comprising a (poly)alcohol and a (poly)isocyanate
  • n two-component systems comprising an ⁇ , ⁇ -ethylenically unsaturated carbonyl compound and a polymer which contains activated CH 2 groups, it being possible for the activated CH 2 groups to be present either in the main chain or in the side chain or in both, as is described, for example, in EP-B-O 161 697 for (poly)malonate groups.
  • Other compounds having activated CH 2 groups are (poly)acetoacetates and (poly)cyanoacetates.
  • the malonate group here can be attached in a polyurethane, polyester, polyacrylate, epoxy resin, poly- amide or polyvinyl polymer either in the main chain or in a side chain.
  • the ⁇ , ⁇ -ethylenically unsaturated carbonyl compound employed can be any double bond activated by a carbonyl group. Examples are esters or amides of acrylic acid or methacrylic acid. In the ester groups it is also possible for additional hydroxyl groups to be present. Diesters and triesters are also possible.
  • Typical examples are hexanediol diacrylate or trimethylolpropane triacrylate.
  • acrylic acid it is also possible to use other acids and their esters or amides, such as crotonic or cinnamic acid.
  • the components of the system react with one another to form a crosslinked coating system which is suitable for numerous applications. Owing to its good inherent weathering resistance it is suitable, for example, for exterior applications as well and can, if required, be additionally stabilised by UV absorbers and other light stabilisers.
  • Epoxy resins are suitable for preparing novel, curable mixtures comprising epoxy resins as component (A) are those which are customary in epoxy resin technology, examples of such epoxy resins being:
  • Polyglycidyl and poly( ⁇ -methylglycidyl) esters obtainable by reacting a compound having at least two carboxyl groups in the molecule with epichlorohydrin or ⁇ -methylepichlorohydrin. The reaction is judiciously carried out in the presence of bases.
  • the compound having at least two carboxyl groups in the molecule it is possible to use aliphatic polycarboxylic acids. Examples of such polycarboxylic acids are oxalic, succinic, glutaric, adipic, pimelic, suberic, azelaic or dimerised or trimerised linoleic acid.
  • Aromatic polycarboxylic acids such as tetrahydrophthalic, 4-methyltetrahydrophthalic, hexa- hydrophthalic or 4-methylhexahydrophthalic acid.
  • Aromatic polycarboxylic acids furthermore, can be used, such as phthalic, isophthalic or terephthalic acid.
  • Polyglycidyl or poly( ⁇ -methylglycidyl) ethers obtainable by reacting a compound having at least two free alcoholic hydroxyl groups and/or phenolic hydroxyl groups with epichlorohydrin or ⁇ -methylepichlorohydrin under alkaline conditions or in the presence of an acidic catalyst with subsequent alkali treatment.
  • the glycidyl ethers of this type are derived, for example, from acyclic alcohols, such as ethylene glycol, diethylene glycol and higher poly(oxyethylene) glycols, propane-1 ,2-diol or poly(oxypropylene) glycols, propane-1 ,3-diol, butane-1 ,4-diol, poly(oxytetramethylene) glycols, pentane-1 ,5-diol, hexane-1 ,6-diol, hexane-2,4,6-triol, glycerol, 1 ,1 ,1 -trimethylolpro- pane, pentaerythritol, sorbitol, and from polyepichlorohydrins.
  • acyclic alcohols such as ethylene glycol, diethylene glycol and higher poly(oxyethylene) glycols, propane-1 ,2-diol or poly(oxypropylene) glycols, propane
  • cycloaliphatic alcohols such as 1 ,4-cyclohexanedimethanol, bis(4-hydroxycyclohexyl)- methane or 2,2-bis(4-hydroxycyclohexyl)propane, or possess aromatic nuclei, such as N, N- bis(2-hydroxyethyl)aniline or p,p'-bis(2-hydroxyethylamino)diphenylmethane.
  • the glycidyl ethers can also be derived from mononuclear phenols, such as resorcinol or hydroquinone, or are based on polynuclear phenols, such as bis(4-hydroxyphenyl)methane, 4,4'-dihydroxy- biphenyl, bis(4-hydroxyphenyl) sulfone, 1 ,1 ,2,2-tetrakis(4-hydroxyphenyl)ethane, 2,2-bis(4- hydroxyphenyl)propane, 2,2-bis(3,5-dibromo-4-hydroxyphenyl)propane and from novolaks, obtainable by condensing aldehydes, such as formaldehyde, acetaldehyde, chloral or furfuraldehyde, with phenols, such as phenol, or with phenols whose nucleus is substituted by chlorine atoms or CrC 9 alkyl groups, examples being 4-chlorophenol, 2-methylphenol
  • Poly(N-glycidyl) compounds obtainable by dehydrochlorination of the reaction products of epichlorohydrin with amines containing at least two active hydrogen bound to amino nitrogen atoms.
  • amines are, for example, aniline, n-butylamine, bis(4-aminophenyl)- methane, m-xylylenediamine or bis(4-methylaminophenyl)methane.
  • the poly(N-glycidyl) compounds also include triglycidyl isocyanurate, N,N'-diglycidyl derivatives of cycloalkylene ureas, such as ethylene urea or 1 ,3-propylene urea, and diglycidyl derivatives of hydantoins, such as of 5,5-dimethylhydantoin.
  • Poly(S-glycidyl) compounds for example di-S-glycidyl derivatives derived from dithiols such as ethane-1 ,2-dithiol or bis(4-mercaptomethylphenyl) ether.
  • Cycloaliphatic epoxy resins for example bis(2,3-epoxycyclopentyl) ether, 2,3-epoxy- cyclopentyl glycidyl ether, 1 ,2-bis(2,3-epoxycyclopentyloxy)ethane or 3,4-epoxycyclohexyl- methyl 3',4'-epoxycyclohexanecarboxylate.
  • epoxy resins in which the 1 ,2-epoxide groups are attached to different heteroatoms and/or functional groups; these compounds include, for example, the N,N,O-triglycidyl derivative of 4-aminophenol, the glycidyl ether glycidyl ester of salicylic acid, N-glycidyl-N'-(2-glycidyloxypropyl)-5,5-dimethylhydantoin or 2-glycidyloxy-1 ,3-bis(5,5-dime- thyl-1-glycidylhydantoin-3-yl)propane.
  • these compounds include, for example, the N,N,O-triglycidyl derivative of 4-aminophenol, the glycidyl ether glycidyl ester of salicylic acid, N-glycidyl-N'-(2-glycidyloxypropyl)-5,5-dimethylhydantoin or 2-glycidy
  • component (A) Mixtures of epoxy resins may also be used as component (A).
  • the present invention is directed to a composition, wherein component (A) is an epoxy resin or a mixture of different epoxy resins.
  • thermolatent base may be used in the curable composition according to the present invention in an amount of from 0.01 to 15% by weight, preferably from 0.1 to 10% by weight and more preferably from 0.1 to 2% by weight, based on the weight of component (A).
  • component (B) i.e. the thermolatent base
  • the component (B) may be used alone or as a combination of two or more of them. Further, they may be used together with known thermolatent bases as a combination. Examples of known thermolatent bases have been described in the documents mentioned in the prior art.
  • thermolatent bases may be N-alkoxycarbonyl imidazoles, as described
  • a photolatent base may be added to the curable composition of the invention.
  • photolatent bases are capped amine compounds, for example compounds of the classes: o-nitrobenzyloxycarbonylamines, 3,5-dimethoxy- ⁇ , ⁇ -dimethylbenzyloxycarbonyl- amines, benzoin carbamates, derivatives of anilides, photolatent guanidines, generally photolatent tertiary amines, for example ammonium salts of ketocarboxylic acids, or other carboxylates, benzhydrylammonium salts, N-(benzophenonylmethyl)-tri-N-alkylammonium triphenylalkyl borates, photolatent bases based on metal complexes, e.g.
  • cobalt amine complexes tungsten and chromium pyridinium pentacarbonyl complexes, anion-generating photoinitators based on metals, such as chromium and cobalt complexes "Reinecke salts" or metalloporphyrins. Examples thereof are published in J.V. Crivello, K. Dietliker "Photoinitiators for Free Radical, Cationic & Anionic Photopolymerisation", Vol. Ill of
  • photolatent base catalyst for the compositions according to the invention are bases as described in WO 97/31033. They are especially latent bases based on secondary amines, guanidines or amidines.
  • photolatent base donors are the ⁇ - aminoketone compounds described in EP-A-O 898 202, for example (4-morpholinobenzoyl)- 1 -benzyl-1 -dimethylamino-propane or (4-methylthiobenzoyl)-1 -methyl-1 -morpholino-ethane.
  • Further interesting photolatent base compounds are of the following structure
  • the photolatent bases may be generally present in an amount of from 0 to 10% by weight, preferably from 0.01 to 10% by weight and more preferably from 0.01 to 2% by weight, based on the weight of component (A).
  • thermolatent base may be used in combination with a further curing catalyst, referred to as component (C), for example another base.
  • Suitable examples are aromatic amines, such as imidazole or substituted imidazoles, e.g. 2-methylimidazole, or pyridine, aliphatic amines, such as 2,2,6,6-tetramethylpiperidine, morpholine, piperazine or piperidine, or amidines, such as 1 ,5-diazabicyclo[4.3.0]non-5-ene (DBN), 1 ,8-diazabicyclo[5.4.0]undec- 7-ene (DBU) or 1 ,4-diazabicyclo[2.2.2]octane (DABCO), or mixtures thereof.
  • aromatic amines such as imidazole or substituted imidazoles, e.g. 2-methylimidazole, or pyridine
  • aliphatic amines such as 2,2,6,6-tetramethyl
  • the additional curing catalyst may be present in the curable composition of the invention in an amount of from 0 to 1 % by weight, preferably from 0.5 to 1 % by weight, based on the weight of component (A).
  • the curable composition of the invention may include, as further additives, i.e. component (D), one or more compounds of the group of the pigments, dyes, fillers, waxes, levelling agents, degassing agents, charge control agents, optical brighteners, adhesion promoters, antioxidants, light stabilizers, plasticizers, rheologic and thixotropic agents or photoinitators.
  • the composition may also include corrosion inhibitors, for example anticorrosion pigments, such as phosphate- or borate-containing pigments or metal oxide pigments, or other organic or inorganic corrosion inhibitors, for example salts of nitroisophthalic acid, phosphoric esters, technical-grade amines or substituted benzotriazoles.
  • the additional additives may usually be added in an amount of from 0 to 20% by weight, preferably of from 0.1 to 15% by weight, based on the weight of component (A).
  • the invention is directed to a curable composition further comprising (C) a curing catalyst other than component (B) and (D) at least one additive.
  • the invention is directed to a curable composition further comprising (C) a curing catalyst other than component (B) and
  • Alkylthiomethylphenols for example 2,4-dioctylthiomethyl-6-tert-butylphenol, 2,4-dioctyl- thiomethyl-6-methylphenol, 2,4-dioctylthiomethyl-6-ethylphenol, 2,6-di-dodecylthiomethyl-4- nonylphenol.
  • Hydroquinones and alkylated hydroquinones for example 2,6-di-tert-butyl-4-methoxy- phenol, 2,5-di-tert-butylhydroquinone, 2,5-di-tert-amylhydroquinone, 2,6-diphenyl-4-octade- cyloxyphenol, 2,6-di-tert-butylhydroquinone, 2,5-di-tert-butyl-4-hydroxyanisole, 3,5-di-tert- butyl-4-hydroxyanisole, 3,5-di-tert-butyl-4-hydroxyphenyl stearate, bis-(3,5-di-tert-butyl-4- hydroxyphenyl) adipate.
  • 2,6-di-tert-butyl-4-methoxy- phenol 2,5-di-tert-butylhydroquinone, 2,5-di-tert-amylhydroquinone, 2,
  • Tocopherols for example ⁇ -tocopherol, ⁇ -tocopherol, ⁇ -tocopherol, ⁇ -tocopherol and mixtures thereof (vitamin E).
  • Hydroxylated thiodiphenyl ethers for example 2,2'-thiobis(6-tert-butyl-4-methylphenol), 2,2'-thiobis(4-octylphenol), 4,4'-thiobis(6-tert-butyl-3-methylphenol), 4,4'-thiobis(6-tert-butyl-2- methylphenol), 4,4'-thiobis-(3,6-di-sec-amylphenol), 4,4'-bis(2,6-dimethyl-4-hydroxyphenyl)- disulfide.
  • 2,2'-thiobis(6-tert-butyl-4-methylphenol 2,2'-thiobis(4-octylphenol), 4,4'-thiobis(6-tert-butyl-3-methylphenol), 4,4'-thiobis(6-tert-butyl-2- methylphenol), 4,4'-thiobis-(3,6-di-sec-amylphenol), 4,4'-bis(
  • Alkylidenebisphenols for example 2,2'-methylenebis(6-tert-butyl-4-methylphenol), 2,2'- methylenebis(6-tert-butyl-4-ethylphenol), 2,2'-methylenebis[4-methyl-6-( ⁇ -methylcyclohexyl)- phenol], 2,2'-methylenebis(4-methyl-6-cyclohexylphenol), 2,2'-methylenebis(6-nonyl-4- methylphenol), 2,2'-methylenebis(4,6-di-tert-butylphenol), 2,2'-ethylidenebis(4,6-di-tert-butyl- phenol), 2,2'-ethylidenebis(6-tert-butyl-4-isobutylphenol), 2,2'-methylenebis[6-( ⁇ -methyl- benzyl)-4-nonylphenol], 2,2'-methylenebis[6-( ⁇ , ⁇ -dimethylbenzylphenol
  • Hydroxybenzylated malonates for example dioctadecyl-2,2-bis-(3,5-di-tert-butyl-2-hy- droxybenzyl)-malonate, di-octadecyl-2-(3-tert-butyl-4-hydroxy-5-methylbenzyl)-malonate, di- dodecylmercaptoethyl-2,2-bis-(3,5-di-tert-butyl-4-hydroxybenzyl)malonate, bis[4-(1 ,1 ,3,3-te- tramethylbutyl)phenyl]-2,2-bis(3,5-di-tert-butyl-4-hydroxybenzyl)malonate.
  • Aromatic hydroxybenzyl compounds for example 1 ,3,5-tris-(3,5-di-tert-butyl-4-hydroxy- benzyl)-2,4,6-trimethylbenzene, 1 ,4-bis(3,5-di-tert-butyl-4-hydroxybenzyl)-2,3,5,6-tetra- methylbenzene, 2,4,6-tris(3,5-di-tert-butyl-4-hydroxybenzyl)phenol. 1.10.
  • Triazine compounds for example 2,4-bis(octylmercapto)-6-(3,5-di-tert-butyl-4-hydroxy- anilino)-1 ,3,5-triazine, 2-octylmercapto-4,6-bis(3,5-di-tert-butyl-4-hydroxyanilino)-1 ,3,5-tri- azine, 2-octylmercapto-4,6-bis(3,5-di-tert-butyl-4-hydroxyphenoxy)-1 ,3,5-triazine, 2,4,6-tris- (3,5-di-tert-butyl-4-hydroxyphenoxy)-1 ,2,3-triazine, 1 ,3,5-tris-(3,5-di-tert-butyl-4-hydroxyben- zyl)isocyanurate, 1 ,3,5-tris(4-tert-butyl-3-hydroxy-2,6-dimethylbenzyl)
  • Benzylphosphonates for example dimethyl-2,5-di-tert-butyl-4-hydroxybenzylphospho- nate, diethyl-3,5-di-tert-butyl-4-hydroxybenzylphosphonate, dioctadecyl3,5-di-tert-butyl-4-hy- droxybenzylphosphonate, dioctadecyl- ⁇ -tert-butyl ⁇ -hydroxy-S-methylbenzylphosphonate, the calcium salt of the monoethyl ester of 3,5-di-tert-butyl-4-hydroxybenzylphosphonic acid.
  • Acylaminophenols for example 4-hydroxylauranilide, 4-hydroxystearanilide, octyl N- (3,5-di-tert-butyl-4-hydroxyphenyl)carbamate.
  • esters of ⁇ -(3,5-di-tert-butyl-4-hvdroxyphenyl)propionic acid with mono- or polyhydric alcohols e.g. with methanol, ethanol, n-octanol, i-octanol, octadecanol, 1 ,6-hexanediol, 1 ,9- nonanediol, ethylene glycol, 1 ,2-propanediol, neopentyl glycol, thiodiethylene glycol, diethy- lene glycol, triethylene glycol, pentaerythritol, tris(hydroxyethyl) isocyanurate, N,N'-bis(hy- droxyethyl)oxamide, 3-thiaundecanol, 3-thiapentadecanol, trimethylhexanediol, trimethylol- propane, 4-hydroxy
  • esters of ⁇ -(5-tert-butyl-4-hvdroxy-3-methylphenyl)propionic acid with mono- or polyhydric alcohols e.g. with methanol, ethanol, n-octanol, i-octanol, octadecanol, 1 ,6-hexanediol, 1 ,9-nonanediol, ethylene glycol, 1 ,2-propanediol, neopentyl glycol, thiodiethylene glycol, diethylene glycol, triethylene glycol, pentaerythritol, tris(hydroxyethyl) isocyanurate, N,N'-bis- (hydroxyethyl)oxamide, 3-thiaundecanol, 3-thiapentadecanol, trimethylhexanediol, trimethyl- olpropane, 4-hydroxymethyl-1-phospha
  • esters of ⁇ -(3,5-dicvclohexyl-4-hvdroxyphenyl)propionic acid with mono- or polyhydric alcohols e.g. with methanol, ethanol, octanol, octadecanol, 1 ,6-hexanediol, 1 ,9-nonanediol, ethylene glycol, 1 ,2-propanediol, neopentyl glycol, thiodiethylene glycol, diethylene glycol, tri- ethylene glycol, pentaerythritol, tris(hydroxyethyl)isocyanurate, N,N'-bis(hydroxyethyl)ox- amide, 3-thiaundecanol, 3-thiapentadecanol, trimethylhexanediol, trimethylolpropane, 4-hy- droxymethyl-1-phospha-2,6,7-trione
  • esters of 3,5-di-tert-butyl-4-hvdroxyphenyl acetic acid with mono- or polyhydric alcohols e.g. with methanol, ethanol, octanol, octadecanol, 1 ,6-hexanediol, 1 ,9-nonanediol, ethylene glycol, 1 ,2-propanediol, neopentyl glycol, thiodiethylene glycol, diethylene glycol, triethylene glycol, pentaerythritol, tris(hydroxyethyl)isocyanurate, N,N'-bis(hydroxyethyl)ox- amide, 3-thiaundecanol, 3-thiapentadecanol, trimethylhexanediol, trimethylolpropane, 4-hy- droxymethyl-1-phospha-2,6,7-trioxabicyclo[
  • Aminic antioxidants for example N,N'-di-isopropyl-p-phenylenediamine, N,N'-di-sec-bu- tyl-p-phenylenediamine, N,N'-bis(1 ,4-dimethylpentyl)-p-phenylenediamine, N,N'-bis(1-ethyl-3- methylpentyl)-p-phenylenediamine, N,N'-bis(1-methylheptyl)-p-phenylenediamine, N,N'-dicy- clohexyl-p-phenylenediamine, N,N'-diphenyl-p-phenylenediamine, N,N'-bis(2-naphthyl)-p- phenylenediamine, N-isopropyl-N'-phenyl-p-phenylenediamine, N-(1 ,3-dimethylbutyl
  • UV absorbers and light stabilisers 2.1.
  • 2-(2'-Hvdroxyphenyl)benzotriazoles for example 2-(2'-hydroxy-5'-methylphenyl)-benzo- triazole, 2-(3',5'-di-tert-butyl-2'-hydroxyphenyl)benzotriazole, 2-(5'-tert-butyl-2'-hydroxyphe- nyl)benzotriazole, 2-(2'-hydroxy-5'-(1 ,1 ,3,3-tetramethylbutyl)phenyl)benzotriazole, 2-(3',5'-di- tert-butyl-2'-hydroxyphenyl)-5-chloro-benzotriazole, 2-(3'-tert-butyl-2'-hydroxy-5'-methylphe- nyl)-5-chloro-benzotriazole, 2-(3'-sec-butyl-5'-tert-butyl-2'-hydroxyphen
  • 2-Hvdroxybenzophenones for example the 4-hydroxy, 4-methoxy, 4-octyloxy, 4-decyl- oxy, 4-dodecyloxy, 4-benzyloxy, 4,2',4'-trihydroxy and 2'-hydroxy-4,4'-dimethoxy derivatives.
  • Esters of substituted and unsubstituted benzoic acids for example 4-tert-butyl-phenyl salicylate, phenyl salicylate, octylphenyl salicylate, dibenzoyl resorcinol, bis(4-tert-butylben- zoyl) resorcinol, benzoyl resorcinol, 2,4-di-tert-butylphenyl 3,5-di-tert-butyl-4-hydroxybenzo- ate, hexadecyl 3,5-di-tert-butyl-4-hydroxybenzoate, octadecyl 3,5-di-tert-butyl-4-hydroxyben- zoate, 2-methyl-4,6-di-tert-butylphenyl 3,5-di-tert-butyl-4-hydroxybenzoate.
  • Acrylates for example ethyl ⁇ -cyano- ⁇ , ⁇ -diphenylacrylate, isooctyl ⁇ -cyano- ⁇ , ⁇ -diphe- nylacrylate, methyl ⁇ -carbomethoxycinnamate, methyl ⁇ -cyano- ⁇ -methyl-p-methoxy-cinna- mate, butyl ⁇ -cyano- ⁇ -methyl-p-methoxy-cinnamate, methyl ⁇ -carbomethoxy-p-methoxycin- namate and N-( ⁇ -carbomethoxy- ⁇ -cyanovinyl)-2-methylindoline.
  • Nickel compounds for example nickel complexes of 2,2'-thio-bis-[4-(1 ,1 ,3,3-tetramethyl- butyl)phenol], such as the 1 :1 or 1 :2 complex, with or without additional ligands such as n- butylamine, triethanolamine or N-cyclohexyldiethanolamine, nickel dibutyldithiocarbamate, nickel salts of the monoalkyl esters, e.g. the methyl or ethyl ester, of 4-hydroxy-3,5-di-tert- butylbenzylphosphonic acid, nickel complexes of ketoximes, e.g. of 2-hydroxy-4-methylphe- nyl-undecylketoxime, nickel complexes of 1-phenyl-4-lauroyl-5-hydroxypyrazole, with or without additional ligands.
  • additional ligands such as n- butylamine, triethanolamine or N-cyclohexyl
  • Sterically hindered amines for example bis(2,2,6,6-tetramethyl-4-piperidyl)sebacate, bis(2,2,6,6-tetramethyl-4-piperidyl)succinate, bis(1 ,2,2,6,6-pentamethyl-4-piperidyl)sebacate, bis(1 -octyloxy-2,2,6,6-tetramethyl-4-piperidyl)sebacate, bis(1 ,2,2,6,6-pentamethyl-4-piperi- dyl) n-butyl-3,5-di-tert-butyl-4-hydroxybenzylmalonate, the condensate of 1-(2-hydroxyethyl)- 2,2,6,6-tetramethyl-4-hydroxypiperidine and succinic acid, linear or cyclic condensates of N,N'-bis(2,2,6,6-tetramethyl-4-piperidyl)hexamethylenediamine and 4-tert-
  • N-(2,2,6,6- tetramethyl-4-piperidyl)-n-dodecylsuccinimide N-(1 , 2,2,6, 6-pentamethyl-4-piperidyl)-n- dodecylsuccinimide
  • 2-undecyl-7,7,9,9-tetramethyl-1 -oxa-3,8-diaza-4-oxo-spiro[4,5]decane a reaction product of 7,7,9,9-tetramethyl-2-cycloundecyl-1-oxa-3,8-diaza-4-oxospiro-
  • Oxamides for example 4,4'-dioctyloxyoxanilide, 2,2'-diethoxyoxanilide, 2,2'-dioctyloxy- 5,5'-di-tert-butoxanilide, 2,2'-didodecyloxy-5,5'-di-tert-butoxanilide, 2-ethoxy-2'-ethyloxanilide, N,N'-bis(3-dimethylaminopropyl)oxamide, 2-ethoxy-5-tert-butyl-2'-ethoxanilide and its mixture with 2-ethoxy-2'-ethyl-5,4'-di-tert-butoxanilide, mixtures of o- and p-methoxy-disubstituted oxanilides and mixtures of o- and p-ethoxy-disubstituted oxanilides.
  • Metal deactivators for example N,N'-diphenyloxamide, N-salicylal-N'-salicyloyl hydrazine, N,N'-bis(salicyloyl) hydrazine, N,N'-bis(3,5-di-tert-butyl-4-hydroxyphenylpropionyl) hydrazine, 3-salicyloylamino-1 ,2,4-triazole, bis(benzylidene)oxalyl dihydrazide, oxanilide, isophthaloyl dihydrazide, sebacoyl bisphenylhydrazide, N,N'-diacetyladipoyl dihydrazide, N,N'-bis(salicyl- oyl)oxalyl dihydrazide, N,N'-bis(salicyloyl)thiopropionyl dihydrazide.
  • Phosphites and phosphonites for example triphenyl phosphite, diphenyl alkyl phosphites, phenyl dialkyl phosphites, tris(nonylphenyl) phosphite, trilauryl phosphite, trioctadecyl phos- phite, distearyl pentaerythritol diphosphite, tris(2,4-di-tert-butylphenyl) phosphite, diisodecyl pentaerythritol diphosphite, bis(2,4-di-tert-butylphenyl) pentaerythritol diphosphite, bis(2,4-di- cumylphenyl) pentaerythritol diphosphite, bis(2,6-di-tert-butyl-4-methylphenyl) pentaerythrito
  • Tris(2,4-di-tert-butylphenyl) phosphite (lrgafos ® 168, Ciba-Geigy), tris(nonylphenyl) phosphite,
  • Hydroxylamines for example N,N-dibenzylhydroxylamine, N,N-diethylhydroxylamine, N, N- dioctylhydroxylamine, N,N-dilaurylhydroxylamine, N,N-ditetradecylhydroxylamine, N, N- dihexadecylhydroxylamine, N,N-dioctadecylhydroxylamine, N-hexadecyl-N-octadecylhydrox- ylamine, N-heptadecyl-N-octadecylhydroxylamine, N,N-dialkylhydroxylamine derived from hydrogenated tallow amine.
  • Nitrones for example N-benzyl-alpha-phenylnitrone, N-ethyl-alpha-methylnitrone, N-octyl- alpha-heptylnitrone, N-lauryl-alpha-undecylnitrone, N-tetradecyl-alpha-tridecylnitrone, N- hexadecyl-alpha-pentadecylnitrone, N-octadecyl-alpha-heptadecylnitrone, N-hexadecyl-al- pha-heptadecylnitrone, N-ocatadecyl-alpha-pentadecylnitrone, N-heptadecyl-alpha-hepta- decylnitrone, N-octadecyl-alpha-hexadecylnitrone, nitrone derived from N,N
  • Thiosynergists for example dilauryl thiodipropionate or distearyl thiodipropionate.
  • Peroxide scavengers for example esters of ⁇ -thiodipropionic acid, for example the lauryl, stearyl, myristyl or tridecyl esters, mercaptobenzimidazole or the zinc salt of 2-mercapto- benzimidazole, zinc dibutyldithiocarbamate, dioctadecyl disulfide, pentaerythritol tetrakis( ⁇ - dodecylmercapto)propionate.
  • esters of ⁇ -thiodipropionic acid for example the lauryl, stearyl, myristyl or tridecyl esters
  • mercaptobenzimidazole or the zinc salt of 2-mercapto- benzimidazole zinc dibutyldithiocarbamate
  • dioctadecyl disulfide pentaerythritol tetrakis( ⁇ - dodecyl
  • Polyamide stabilisers for example copper salts in combination with iodides and/or phosphorus compounds and salts of divalent manganese.
  • Basic co-stabilisers for example melamine, polyvinylpyrrolidone, dicyandiamide, triallyl cyanurate, urea derivatives, hydrazine derivatives, amines, polyamides, polyurethanes, alkali metal salts and alkaline earth metal salts of higher fatty acids, for example calcium stearate, zinc stearate, magnesium behenate, magnesium stearate, sodium ricinoleate and potassium palmitate, antimony pyrocatecholate or zinc pyrocatecholate.
  • Basic co-stabilisers for example melamine, polyvinylpyrrolidone, dicyandiamide, triallyl cyanurate, urea derivatives, hydrazine derivatives, amines, polyamides, polyurethanes, alkali metal salts and alkaline earth metal salts of higher fatty acids, for example calcium stearate, zinc stearate, magnesium behenate, magnesium stearate, sodium ric
  • Nucleating agents for example inorganic substances, such as talcum, metal oxides, such as titanium dioxide or magnesium oxide, phosphates, carbonates or sulfates of, preferably, alkaline earth metals; organic compounds, such as mono- or polycarboxylic acids and the salts thereof, e.g. 4-tert-butylbenzoic acid, adipic acid, diphenylacetic acid, sodium succinate or sodium benzoate; polymeric compounds, such as ionic copolymers (ionomers).
  • inorganic substances such as talcum, metal oxides, such as titanium dioxide or magnesium oxide, phosphates, carbonates or sulfates of, preferably, alkaline earth metals
  • organic compounds such as mono- or polycarboxylic acids and the salts thereof, e.g. 4-tert-butylbenzoic acid, adipic acid, diphenylacetic acid, sodium succinate or sodium benzoate
  • polymeric compounds such as ionic copolymers (
  • Fillers and reinforcing agents for example calcium carbonate, silicates, glass fibres, glass bulbs, asbestos, talc, kaolin, mica, barium sulfate, metal oxides and hydroxides, carbon black, graphite, wood flour and flours or fibers of other natural products, synthetic fibers.
  • additives for example plasticisers, lubricants, levelling agents, emulsifiers, pigments, rheologic and thixotropic agents, flow-control agents, optical brighteners, flameproofing agents, antistatic agents and blowing agents.
  • the composition may also include other binders as well. It is possible to use, for example, further olefinically unsaturated compounds.
  • the unsaturated compounds may include one or more olefinic double bonds. They may be of low molecular mass (monomeric) or higher molecular mass (oligomeric).
  • Examples of monomers having a double bond are alkyl acrylates or hydroxyalkyl acrylates or alkyl methacrylates or hydroxyalkyl methacrylates, such as methyl, ethyl, butyl, 2-ethylhexyl or 2-hydroxyethyl acrylate, isobornyl acrylate, methyl methacrylate or ethyl methacrylate. Silicone acrylates are also of interest.
  • acrylonitrile acrylamide, methacrylamide, N-substituted (meth)acrylamides
  • vinyl esters such as vinyl acetate
  • vinyl ethers such as isobutyl vinyl ether
  • styrene alkyl- and halostyrenes
  • N-vinylpyrrolidone vinyl chloride or vinylidene chloride.
  • Examples of monomers having several double bonds are the diacrylates of ethylene glycol, propylene glycol, neopentyl glycol, hexamethylene glycol or bisphenol A, 4,4'-bis(2-acryloyl- oxyethoxy)diphenylpropane, trimethylolpropane triacrylate, pentaerythritol triacrylate or pentaerythritol tetraacrylate, vinyl acrylate, divinyl benzene, divinyl succinate, diallyl phtha- late, triallyl phosphate, triallyl isocyanurate or tris(2-acryloylethyl)isocyanurate.
  • polyunsaturated compounds of high molecular mass examples include acrylated epoxy resins, acrylated polyesters or polyesters containing vinyl ether groups or epoxy groups, polyurethanes and polyethers.
  • unsaturated oligomers are unsaturated polyester resins which are mostly prepared from maleic acid, phthalic acid and one or more diols and have molecular weights of about 500 to 3000.
  • vinyl ether monomers and oligomers and also maleate-terminated oligo- mers with polyester, polyurethane, polyether, polyvinyl ether and epoxy main chains.
  • esters of ethylenically unsaturated carboxylic acids and polyols or polyepoxides and polymers having ethylenically unsaturated groups in the chain or in side groups, such as unsaturated polyesters, polyamides and polyurethanes and copolymers thereof, alkyd resins, polybutadiene and butadiene copolymers, polyisoprene and isoprene copolymers, polymers and copolymers having (meth)acrylic groups in side chains, and mixtures of one or more such polymers.
  • Examples are benzophenone, benzophenone derivatives, acetophenone, acetophenone derivatives, for example ⁇ -hydroxycycloalkyl phenyl ketones, dialkoxyacetophenones, ⁇ -hydroxy- or ⁇ - aminoacetophenones, 4-aroyl-1 ,3-dioxolanes, benzoin alkyl ethers and benzil ketals, monoacyl phosphine oxides, bisacylphosphine oxides, ferrocenium compounds or titanocenes.
  • non-reactive binders to the novel compositions, which is particularly judicious if the anionically polymerisable or crosslinkable organic material, component (A) is a liquid or viscous substance.
  • the amount of the non-reactive binder may be, for example, 5- 95%, preferably 10-90% and, in particular, 40-90% by weight, based on the weight of component (A).
  • the choice of non-reactive binder is made in accordance with the field of use and with the properties required for this use, such as the possibility for development in aqueous and organic solvent systems, adhesion to substrates, and sensitivity to oxygen.
  • Suitable binders are polymers having a molecular weight of around 5000- 2,000,000, preferably 10,000-1 ,000,000.
  • suitable binders are polymers having a molecular weight of around 5000- 2,000,000, preferably 10,000-1 ,000,000.
  • suitable binders are polymers having a molecular weight of around 5000- 2,000,000, preferably 10,000-1 ,000,000.
  • suitable binders are polymers having a molecular weight of around 5000- 2,000,000, preferably 10,000-1 ,000,000.
  • suitable binders are polymers having a molecular weight of around 5000- 2,000,000, preferably 10,000-1 ,000,000.
  • suitable binders are polymers having a molecular weight of around 5000- 2,000,000, preferably 10,000-1 ,000,000.
  • suitable binders are polymers having a molecular weight of around 5000- 2,000,000, preferably 10,000-1 ,000,000.
  • suitable binders are polymers having a molecular weight of around 5000- 2,000,000, preferably 10,000-1 ,000,000.
  • suitable binders are
  • the curable compositions according to the invention are prepared according to methods known in the art.
  • the component (B), i.e. the thermolatent base represented by formula (I), and optional further additives may be added to component (A), i.e. an anionically polymerisable or crosslinkable organic material, and optional additional binders, individually or mixed with one another.
  • component (B) and optional further additives into component (A) and optional binders is carried out by known methods such as dry mixing in the form of powder or wet mixing in the form of solutions or suspensions.
  • Suitable solvents are, for example, dimethyl formamide, tetrahydrofurane, methyl ethyl ketone or ethyl acetate.
  • Usual mixing apparatus are, for example, stirrers, kneaders, rollers, or in case of solid substances dry mixers.
  • novel curable compositions may be employed for various purposes, preferably as coating compositions.
  • the novel curable compositions are suitable, for example, as coating materials for substrates of all kinds, examples being wood, textiles, paper, ceramic, glass, plastics such as polyesters, polyethylene terephthalate, polyolefins or cellulose acetate, especially in the form of films, and also metals such as Al, Cu, Ni, Fe, Zn, Mg or Co and GaAs, Si or SiO 2 .
  • the instant coating compositions are particularly suitable both for metal finish coatings and solid shade finishes of automobiles, especially in the case of retouching finishes, as well as various coil coating applications.
  • the coating compositions in accordance with the invention are preferably applied in the conventional manner by two methods, either by the single-coat method or by the two-coat method. In the latter method, a pigment-containing base coat is applied first and then a covering coat of clear lacquer over it.
  • ammonium salts of acid groups present in the resin are formed.
  • thermolatent bases, component (B) are particularly useful when no organic solvent or water is present in the coating composition. This is typically the case for powder coatings.
  • Powder coating is a known technology and is described, for example, in "Ullmann's Encyclopedia of Industrial Chemistry, Fifth, Completely Revised Edition, Volume A 18", pages 438 to 444 (1991 ).
  • a powder is generally fluidized with supply of air, electrostatically charged and applied to an earthed, preferably metallic substrate.
  • the substrate is subsequently heated, in the course of which the adhering powder melts, coalesces and forms a coherent film on the metal surface. Since powder coating requires no solvent, this technology is especially friendly to the environment.
  • the manner in which the powder is brought into contact with the workpiece to be coated characterizes the various application techniques, for example electrostatic powder spraying with corona or triboelectric pistols, electrostatic fluidized-bed sintering or by using magnetic brush technology.
  • novel curable compositions may also be employed as adhesives, including pressure sensitive adhesives, as laminating resins, for the coating or encapsulation of electrical or electronic components, or as coatings for optical fibres.
  • the curable composition of the invention as a liquid composition, a solution or suspension to the substrate.
  • the choice of solvent and the concentration depend predominantly on the type of composition and the coating process.
  • the solvent should be inert: in other words, it should not undergo any chemical reaction with the components and should be capable of being removed again after the coating operation, in the drying process.
  • suitable solvents are ketones, ethers and esters, such as methyl ethyl ketone, isobutyl methyl ketone, cyclopentanone, cyclohexanone, N-methylpyrrolidone, dioxane, tetrahydrofuran, 2-methoxyethanol, 2-ethoxyethanol, 1-methoxy-2-propanol, 1 ,2- dimethoxyethane, ethyl acetate, n-butyl acetate and ethyl 3-ethoxypropionate.
  • ketones such as methyl ethyl ketone, isobutyl methyl ketone, cyclopentanone, cyclohexanone, N-methylpyrrolidone, dioxane, tetrahydrofuran, 2-methoxyethanol, 2-ethoxyethanol, 1-methoxy-2-propanol, 1 ,2- dimethoxyethane, ethyl acetate
  • the solution is applied uniformly to a substrate, for example by spin coating, dip coating, knife coating, curtain coating, brushing, spraying, especially by electrostatic spraying and reverse roll coating, and by electrophoretic deposition.
  • the amount applied (layer thickness) and the nature of the substrate (layer support) are functions of the desired field of application.
  • the range of layer thicknesses generally comprises values from about 0.1 ⁇ m to more than 100 ⁇ m.
  • Thermal curing means generally heating the composition at a temperature between 60 0 C and 250 0 C, preferably between 80 0 C and 150 0 C. In case of thermosetting powder coatings the preferred temperature range is between 120°C and 200 0 C.
  • the composition may be cured by subjecting the composition to irradiation with a light having a wavelength of from 200 nm to 650 nm, preferably 250 nm to 400 nm.
  • Curing time may be, for example, in the range of from 1 to 60 minute for thermosetting coatings.
  • This invention also relates to the use of a compound of formula (I)
  • the invention relates to the use of the compound of formula (I) for the preparation of coating compositions, especially powder coating compositions, or adhesive compositions.
  • this invention relates to polymerised or crosslinked novel compositions, for example coatings or bonded material produced by curing of a curable composition of the present invention, as described above.
  • this invention relates to a coating or a bonded article which coating or bonded article comprises a compound of formula (V)
  • R 1 , R 2 , R 3 , R 4 , R 5 and p are as defined above, and a polymerised or crosslinked organic material.
  • R 1 is a C 2 -C 2 oring system, either a monocyclic ring system, which contains up to two heteroatoms of S or N or a polycyclic ring system, which contains one or more heteroatoms of S or N, said ring system is unsubstituted or substituted by
  • Ci-Ci 8 alkyl CrCi 8 alkyl, which is substituted by E and/or interrupted by D; C 5 -Ci 2 cycloalkyl;
  • C 5 -Ci 2 cycloalkyl which is substituted by E and/or interrupted by D; C 2 -Ci 8 alkenyl; C 2 -Ci 8 alkinyl; C 6 -Ci 8 aryl; C 6 -Ci 8 aryl, which is substituted by G; C 2 -Ci 8 heteroaryl; C 2 -
  • Ci 8 heteroaryl which is substituted by G; Ci-Ci 8 alkoxy; Ci-Ci 8 alkoxy, which is substituted by
  • R 2 , R 3 , R 4 and R 5 are independently of each other and each R 4 or R 5 independently from any other R 4 or R 5 are H; Ci-Ci 8 alkyl; Ci-Ci 8 alkyl, which is substituted by E and/or interrupted by D; C 5 -Ci 2 cycloalkyl; C 5 -Ci 2 cycloalkyl, which is substituted by E; C 6 -Ci 2 aryl; C 6 -Ci 8 aryl, which is substituted by G; C 2 -Ci 8 heteroaryl; C 2 -Ci 8 heteroaryl, which is substituted by G; d-Ci 8 alkoxy; Ci-Ci 8 alkoxy, which is substituted by E and/or interrupted by D; C 7 -Ci 8 aralkyl; C 7 -Ci 8 aralkyl, which is substituted by G; NHR 18 , NR 19 R 20 , COOH;
  • R 2 and R 3 , R 4 and R 5 , or R 2 and R 4 form an organic bridging group completing, together with the carbon atom, they are linked to, a carbocyclic or heterocyclic ring of 5 to 12 ring atoms in total; or two of R 5 , which are linked to adjacent carbon atoms, form an organic bridging group completing, together with the carbon atom, they are linked to, a carbocyclic or heterocyclic ring of 5 to 12 ring atoms in total;
  • E is OR 27 ; SR 28 ; SOR 29 ; SO 2 R 30 ; NR 31 R 32 ; COR 33 ; COOR 34 ; CONR 35 R 36 ; PO(R 37 ) 2 ; Si(R 38 ) 3 ; CN; Cl, Br, or I; and G is E or Ci-Ci 8 alkyl;
  • R 27 , R 28 , R 29 , R 30 , R 31 , R 32 , R 33 , R 34 , R 35 R 36 , R 37 and R 38 are independently of each other C r Ci 8 alkyl; Ci-Ci 8 alkyl, which is interrupted by -0-; C 6 -Ci 8 aryl; C 6 -Ci 8 aryl, which is substituted by Ci-Ci 8 alkyl or Ci-Ci 8 alkoxy; C 7 -Ci 8 aralkyl; C 7 -Ci 8 aralkyl, which is substituted by G; C 2 -Ci 8 heteroaryl;
  • R 7 and R 8 , R 9 and R 10 , R 16 and R 17 , R 19 and R 20 , R 29 and R 30 , or R 33 and R 34 form an organic bridging group completing, together with the nitrogen atom, they are linked to, a heterocyclic ring of 5 to 7 ring atoms in total;
  • R 80 is Ci-Ci 8 alkoxy, OC 6 -Ci 8 aryl, NHC 6 -Ci 8 aryl, NHC r Ci 8 alkyl; p is an integer of 1 or 2, with the proviso that, if p is 1 and the ring system is pyridine or pyrimidine, R 3 and R 4 is not phenyl, or , if p is 1 and the rig system is pyrimidine, said pyrimidine ring is not substituted by halogen.
  • Preferred compounds are compounds of formula (III), wherein R 1 is a mono- or polycyclic C 2 -C 20 ring system, which contains up to 2 heteroatoms of S or N and/or is unsubstituted or substituted by Ci-Ci 8 alkyl;
  • R 2 , R 3 , R 4 and R 5 are independently of each other and each R 4 or R 5 independently from any other R 4 or R 5 are H or Ci-Ci 8 alkyl
  • R 80 is Ci-Ci 8 alkoxy, OC 6 -Ci8aryl, NHC 6 -Ci8aryl, NHCi-Ci 8 alkyl
  • p is an integer of 1 or 2.
  • the compounds of component (B) may be prepared by various known techniques.
  • one method of preparation consists of reacting a halo-substituted heterocycle with an appropriate amine, as described by D. -H. Yang et al., J. Chem. Res. 9, 2006, 600-601 , V. Birman et al., Org. Lett. 9(1 ), 2007, 37-40 or MJ. Weiss, CR. Hauser, J. Am. Chem. Soc. 72, 1950, 1858-1859.
  • Another way of preparation is reacting an amino-substituted heterocycle with a suitable epoxide or an alkylating agent, as described by A.P. Gray et al., J. Am. Chem.
  • the hydroxy or amino group of the component (B), corresponding to the leaving group L in formula (I), may be further modified to obtain a better nucleophilic group L.
  • the curable compositions of the present invention have excellent storage stability by using thermolatent amidine bases described above. So-called one-pot systems with base- polymerisable oligomers or monomers have an extremely long storage life without special precautions which offer an advantage in terms of reduced handling prior immediate use and lower amounts of waste due to better pot-life.
  • the doctorability time i.e. the period before the compositions cures, which is needed to handle the composition is increased.
  • the curable compositions may be prepared by elevated temperature, for example by extrusion which is of particular interest for the production of powder coatings.
  • powder coatings may be obtained at temperatures lower than the temperature which may activate the thermolatent base.
  • Suitable temperature for manufacturing powder coatings may be of from 80 to 120 0 C.
  • the coatings obtained by curing the composition of the invention show less yellowing at the time after preparation as well as after a certain time. Moreover, the leveling of coatings, preferably those obtained by applying a powder coating of the invention, is improved.
  • Apparatus, etc. employed in measurement are as follows: 1H NMR: Bruker 300 MHz spectrometer IR spectroscopy: Nicolet 380 FT-IR spectrometer
  • the compound is prepared according to V. Birman et al., J. Am. Chem. Soc. 126, 2004, 12226-12227.
  • the compound is prepared according to V. Birman et al., J. Am. Chem. Soc. 126, 2004, 12226-12227.
  • the compound is prepared as described by K. Kovacs, T. Vajda, Chemistry & Industry, 1959, 259.
  • a solution of 2.62 g (0.012 mol) of di-tert-butyl-dicarbonate in 4 ml of tetrahydrofurane is added to a solution of 1.52 g (0.01 mol) of 3-(pyridine-2-ylamino)-propane-1-ol (10), 0.055g of 4-dimethylamino-pyridine and 2.8 ml (0.02 mol) of triethylamine in 2 ml of tetrahydrofurane, and the resulting mixture is stirred at room temperature for 24 hours.
  • the compound is prepared as described by T. Yamazaki et al., Yakugaku Zasshi, 88(2), 1968, 212-215.
  • the compound is prepared as described by M. Nagata et al., Yakugaku Zasshi, 83, 1963, 682-689.
  • a mixture of 8.15 g (0.05 mol) of 2-chloroquinoline and 15.3 g (0.15 mol) of 3- dimethylaminopropylamine is heated at 170 0 C for 17 hours.
  • the resulting mixture is then cooled to room temperature, and 80 ml of ice water is added thereto.
  • the precipitated oil is extracted with 10 ml of dichloromethane, the resulting solution is washed with 40 ml of water and 25 ml of 2M Na 2 CO 3 , the separated organic phase is dried over MgSO 4 and evaporated to obtain 9.5 g 16 as a light yellow oil.
  • the compound is prepared as desribed by V. Birman et al., Org. Lett. 9(1 ), 2007, 37-40.
  • the compound is prepared as desribed by M. Kobayashi et al., Tetrahedron Lett., 47(26), 2006, 4347-4350.
  • the compound is prepared as desribed by A.M. Simonov et al., Khimiya Geterotsiklicheskikh Soedinenii, 6, 1975, 826-828.
  • the compound is prepared as desribed by V.A. Anisimova et al., Pharm. Chem. J. 36(9), 2002, 468-473.
  • the compound is prepared as desribed by R. C. Clapp et al., J. Org. Chem., 28(8), 1964, 2172-2174.
  • the compound is prepared as desribed by R. C. Clapp et al., J. Heterocycl. Chem., 7(6), 1970, 1357-1361.
  • the compound is prepared as desribed by I.N. Goncharov et al., Zhurnal Obshchei Khimii 32, 1962, 3332-3339.
  • the compound is prepared as desribed by R.N. Castle et al., J. Heterocycl. Chem., 3(3), 1966, 381-383.
  • the compound is prepared as desribed by K. Bhandari et al., Indian. J. Chem., Sect. B, 17B(2), 1979, 107-110.
  • the compound is prepared as desribed by J.N. Singh et al., J. Indian Chem. Soc. 43(5), 1966, 308-310.
  • the compound is prepared as desribed by G. Cignarella et al., J. Med. Chem. 8(3), 1965, 326-331.
  • a powder coating formulation consisting of an acidic functional polyester and an epoxy functional polymer that cures without a catalyst at 200 0 C for 20 minutes is used.
  • the solid coating formulation is dissolved at 50% solids in methyl-iso-butyl ketone for ease of application.
  • the curing catalyst is added in varying amounts from 0.5 up to 1.5 % by weight, based on solids.
  • the thermolatent compounds are compared with imidazole or compound 1 as a reference base.
  • the formulation is applied at wet thickness 250 ⁇ m using a wire bar.
  • the solvent is evaporated at room temperature during 30 minutes, and the coating formulation is cured for given times and at the specified temperature (cf. Tables 2 to 4).
  • the curing progress is evaluated using attenuated total reflection infrared (IR) spectroscopy.
  • IR total reflection infrared
  • the color deviation or yellowing, resp., in ⁇ E is determined according to the CIELAB system. It is found that at a conversion after 15 min at 120 0 C ⁇ E of the composition comprising 1 is 30% better than the corresponding value of the composition comprising imidazole.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Paints Or Removers (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Epoxy Resins (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne des compositions durcissables qui comprennent une base amidine thermolatente et un matériau organique qui est polymérisable ou réticulable avec un catalyseur basique ou nucléophile. L’invention concerne notamment des compositions de revêtement durcissables, en particulier des compositions de revêtement sous la forme de poudres, et des compositions adhésives durcissables, ainsi que l’utilisation d’une amidine thermolatente en tant que catalyseur de durcissement pour des réactions de polymérisation ou de réticulation catalysées par des bases et induites thermiquement.
PCT/EP2009/065394 2008-11-24 2009-11-18 Composition durcissable comprenant une base thermolatente Ceased WO2010057922A1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
EP09755900A EP2367794B1 (fr) 2008-11-24 2009-11-18 Composition durcissable comprenant une base thermolatente
KR1020117014449A KR101239571B1 (ko) 2008-11-24 2009-11-18 열잠재성 염기를 포함하는 경화성 조성물
CN200980147096.1A CN102224140B (zh) 2008-11-24 2009-11-18 包含热潜性碱的可固化组合物
ES09755900T ES2400633T3 (es) 2008-11-24 2009-11-18 Composición curable que comprende una base termolatente
BRPI0921185A BRPI0921185A2 (pt) 2008-11-24 2009-11-18 composição curável, artigo para revestimento ou ligado, uso de um composto, e, composto
US13/130,331 US8969577B2 (en) 2008-11-24 2009-11-18 Curable composition comprising a thermolatent base
PL09755900T PL2367794T3 (pl) 2008-11-24 2009-11-18 Utwardzalna kompozycja zawierająca aktywowaną termicznie utajoną zasadę
JP2011536854A JP5250116B2 (ja) 2008-11-24 2009-11-18 熱潜在性塩基を含む硬化性組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08169738 2008-11-24
EP08169738.5 2008-11-24

Publications (2)

Publication Number Publication Date
WO2010057922A1 true WO2010057922A1 (fr) 2010-05-27
WO2010057922A4 WO2010057922A4 (fr) 2010-08-19

Family

ID=40810873

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/065394 Ceased WO2010057922A1 (fr) 2008-11-24 2009-11-18 Composition durcissable comprenant une base thermolatente

Country Status (9)

Country Link
US (1) US8969577B2 (fr)
EP (1) EP2367794B1 (fr)
JP (1) JP5250116B2 (fr)
KR (1) KR101239571B1 (fr)
CN (1) CN102224140B (fr)
BR (1) BRPI0921185A2 (fr)
ES (1) ES2400633T3 (fr)
PL (1) PL2367794T3 (fr)
WO (1) WO2010057922A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012152859A1 (fr) 2011-05-10 2012-11-15 Arkema France Resines et composites hybrides thermodurs/supramoleculaires pouvant etre faconnes a chaud et recycles
WO2016124493A1 (fr) 2015-02-02 2016-08-11 Basf Se Acides latents et leur utilisation

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014186151A1 (fr) * 2013-05-14 2014-11-20 3M Innovative Properties Company Résines époxy comprenant un composé contenant de la pyrazine
KR101987305B1 (ko) * 2013-11-19 2019-06-10 삼성전기주식회사 인쇄회로기판용 절연 수지 조성물 및 이를 이용한 제품
JP2016079173A (ja) * 2014-10-15 2016-05-16 日本合成化学工業株式会社 新規ピリジン系化合物、それを用いたアニオン硬化性化合物用硬化剤、硬化性組成物及び硬化物
US10160865B2 (en) 2017-05-05 2018-12-25 TIGER DRYLAC U.S.A. Inc. Low gloss hybrid powder coating
US10428224B2 (en) 2017-05-24 2019-10-01 TIGER DRYLAC U.S.A. Inc. Low gloss powder coating
US10773243B2 (en) 2017-09-07 2020-09-15 Ppg Industries Ohio, Inc. Thermolatent catalyst and its use in curable compositions
CN111801306A (zh) * 2017-12-27 2020-10-20 巴斯夫欧洲公司 含亚甲基丙二酸酯单体和聚合物的组合物、其制备及其在地板应用中的用途

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB901311A (en) * 1958-11-04 1962-07-18 Irwin Neisler & Co Pyridylamino lower alkane derivatives and processes for preparing them
US3165527A (en) * 1960-11-03 1965-01-12 Neisler Lab Inc Pyridyl amino lower alkane derivatives and process
US3192216A (en) * 1961-10-30 1965-06-29 Neisler Lab Inc Phenylhydroxyalkylpyrimidine compounds
US4189543A (en) * 1978-08-21 1980-02-19 The Dow Chemical Company Catalyst for making polyurethanes
JPH04275278A (ja) * 1991-03-04 1992-09-30 Agro Kanesho Co Ltd フェニルカーバメート誘導体、その製造法及び該誘導体を有効成分とする農園芸用殺菌剤
JPH07138237A (ja) * 1993-11-19 1995-05-30 Ube Ind Ltd ４−アミノピリミジン誘導体、その製法及び農園芸用の有害生物防除剤
WO1998004531A1 (fr) * 1996-07-26 1998-02-05 Ciba Specialty Chemicals Holding Inc. Melanges durcissables a base de resines epoxy contenant des imidazoles
JP2004346016A (ja) * 2003-05-22 2004-12-09 Otsuka Chemical Co Ltd トリフルオロメチルキノキサリン化合物、その製造方法、及び有害生物防除剤

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3220846A (en) 1960-06-27 1965-11-30 Eastman Kodak Co Use of salts of readily decarboxylated acids in thermography, photography, photothermography and thermophotography
US3553292A (en) * 1968-12-10 1971-01-05 Grace W R & Co Product and a method of improving the shelf life of uncured polyesters
US3709904A (en) * 1969-06-18 1973-01-09 Dow Chemical Co Aminoethylation reaction and products thereof
US3819626A (en) 1972-09-11 1974-06-25 Chevron Res Substituted triazines
US3938985A (en) 1972-09-11 1976-02-17 Chevron Research Company Substituted triazines
US3784508A (en) * 1972-09-15 1974-01-08 Dow Chemical Co Rapid cure polyepoxide oxazine or oxazoline systems
JPS50155625A (fr) 1974-06-03 1975-12-16
US4088496A (en) 1976-12-22 1978-05-09 Eastman Kodak Company Heat developable photographic materials and process
US4156677A (en) * 1977-06-28 1979-05-29 Union Carbide Corporation Polymer composite articles containing amino substituted mercapto organo silicon coupling agents
US4147712A (en) * 1977-06-28 1979-04-03 Union Carbide Corporation Amino substituted mercapto organosilicon compounds
US4218513A (en) * 1977-06-28 1980-08-19 Union Carbide Corporation Polymer composite articles containing amino substituted mercapto organo silicon coupling agents
EP0027913A3 (fr) * 1979-10-26 1981-10-21 Ciba-Geigy Ag Matériau pour l'enregistrement sensible à la pression ou à la chaleur
JPS59157637A (ja) 1983-02-25 1984-09-07 Fuji Photo Film Co Ltd 熱現像カラ−感光材料
JPS59168440A (ja) 1983-03-16 1984-09-22 Fuji Photo Film Co Ltd 熱現像カラ−感光材料
JPS6153636A (ja) 1984-08-24 1986-03-17 Fuji Photo Film Co Ltd 熱現像感光材料
JPS62161819A (ja) 1986-01-09 1987-07-17 Dainippon Ink & Chem Inc エポキシ樹脂組成物
JPH0788421B2 (ja) * 1987-10-26 1995-09-27 武田薬品工業株式会社 架橋樹脂の製造方法
JPS63288180A (ja) * 1988-05-07 1988-11-25 株式会社三共 弾球遊技機の制御装置
JPH0578502A (ja) * 1991-09-18 1993-03-30 Fujitsu Ltd エポキシ系ポリマー薄膜の形成方法
US5296486A (en) 1991-09-24 1994-03-22 Boehringer Ingelheim Pharmaceuticals, Inc. Leukotriene biosynthesis inhibitors
US6525067B1 (en) 1999-11-23 2003-02-25 Pfizer Inc Substituted heterocyclic derivatives
CN1232515C (zh) 2000-03-31 2005-12-21 亨凯尔公司 包含环氧乙烷或硫杂丙环的树脂和固化剂的可再加工的组合物
DE10028402A1 (de) 2000-06-13 2001-12-20 Merck Patent Gmbh Pyridin-2-yl-aminoalkycarbonylglycyl-beta-alanin und Derivate
JP2003021883A (ja) * 2001-07-09 2003-01-24 Konica Corp 膜強度を改良した熱現像感光材料
US6699651B1 (en) 2002-11-20 2004-03-02 Eastman Kodak Company Base precursors for use in a photothermographic element
GB0324551D0 (en) 2003-10-21 2003-11-26 Karobio Ab Novel compounds
HRP20120901T1 (hr) 2004-03-05 2012-12-31 F. Hoffmann - La Roche Ag Diaminopirimidini kao p2x3 i p2x2/3
EP1922311A2 (fr) 2005-09-09 2008-05-21 Brystol-Myers Squibb Company Inhibiteurs d'ikur acycliques

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB901311A (en) * 1958-11-04 1962-07-18 Irwin Neisler & Co Pyridylamino lower alkane derivatives and processes for preparing them
US3165527A (en) * 1960-11-03 1965-01-12 Neisler Lab Inc Pyridyl amino lower alkane derivatives and process
US3192216A (en) * 1961-10-30 1965-06-29 Neisler Lab Inc Phenylhydroxyalkylpyrimidine compounds
US4189543A (en) * 1978-08-21 1980-02-19 The Dow Chemical Company Catalyst for making polyurethanes
JPH04275278A (ja) * 1991-03-04 1992-09-30 Agro Kanesho Co Ltd フェニルカーバメート誘導体、その製造法及び該誘導体を有効成分とする農園芸用殺菌剤
JPH07138237A (ja) * 1993-11-19 1995-05-30 Ube Ind Ltd ４−アミノピリミジン誘導体、その製法及び農園芸用の有害生物防除剤
WO1998004531A1 (fr) * 1996-07-26 1998-02-05 Ciba Specialty Chemicals Holding Inc. Melanges durcissables a base de resines epoxy contenant des imidazoles
JP2004346016A (ja) * 2003-05-22 2004-12-09 Otsuka Chemical Co Ltd トリフルオロメチルキノキサリン化合物、その製造方法、及び有害生物防除剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LESLIE M. WERBEL, JOSEPHINE R. BATTAGLIA: "Derivatives of 2-amino-5-nitrothiazole as potential schistosomicides", J. MED. CHEM., vol. 14, no. 1, 1971, pages 10 - 16, XP002539378 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012152859A1 (fr) 2011-05-10 2012-11-15 Arkema France Resines et composites hybrides thermodurs/supramoleculaires pouvant etre faconnes a chaud et recycles
FR2975101A1 (fr) * 2011-05-10 2012-11-16 Arkema France Resines et composites hybrides thermodurs / supramoleculaires pouvant etre faconnes a chaud et recycles
US9359467B2 (en) 2011-05-10 2016-06-07 Arkema France Thermoset/supramolecular hybrid composites and resins that can be hot-formed and recycled
WO2016124493A1 (fr) 2015-02-02 2016-08-11 Basf Se Acides latents et leur utilisation
US9994538B2 (en) 2015-02-02 2018-06-12 Basf Se Latent acids and their use

Also Published As

Publication number Publication date
KR101239571B1 (ko) 2013-03-06
CN102224140B (zh) 2014-04-16
ES2400633T3 (es) 2013-04-11
JP2012509949A (ja) 2012-04-26
BRPI0921185A2 (pt) 2018-05-29
JP5250116B2 (ja) 2013-07-31
EP2367794A1 (fr) 2011-09-28
US20110245375A1 (en) 2011-10-06
US8969577B2 (en) 2015-03-03
EP2367794B1 (fr) 2013-01-09
PL2367794T3 (pl) 2013-06-28
CN102224140A (zh) 2011-10-19
WO2010057922A4 (fr) 2010-08-19
KR20110097892A (ko) 2011-08-31

Similar Documents

Publication Publication Date Title
WO2010057922A1 (fr) Composition durcissable comprenant une base thermolatente
KR101322194B1 (ko) 장파장 천이된 벤조트리아졸 ｕｖ 흡수제 및 이의 용도
JP5301434B2 (ja) 長波長シフトしたベンゾトリアゾール紫外線吸収剤およびその使用
WO2010142576A1 (fr) Nouveaux photostabilisants d'amine à encombrement stérique
US20130143051A1 (en) Hydroxyphenyl triazines with an aromatic carbocyclic fused ring system
WO2010142572A1 (fr) Stabilisants d'amines à encombrement stérique
EP1893707B1 (fr) Compositions de revetement pour automobile comprenant des tris(hydroxyphenyl)triazines
JP2008545865A5 (fr)
RU2487867C2 (ru) Отверждаемая композиция, содержащая термолатентное основание
WO2002079182A2 (fr) Processus catalyse par un metal de transition pour la preparation d'alcoxyamines n-substituees et steriquement encombrees
EP1341775A2 (fr) Procede de preparation de morpholinones pouvant servir de photostabilisants

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980147096.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09755900

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009755900

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011536854

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 4365/CHENP/2011

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 13130331

Country of ref document: US

ENP Entry into the national phase

Ref document number: 20117014449

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2011125707

Country of ref document: RU

ENP Entry into the national phase

Ref document number: PI0921185

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20110524